# reload+after+2024-01-23 18:43:43.146835
address1§12750 High Bluff Drive
address2§Suite 475
city§San Diego
state§CA
zip§92130
country§United States
phone§858 246 6240
website§https://belitebio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
fullTimeEmployees§16
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Yu-Hsin  Lin M.B.A., Ph.D.', 'age': 44, 'title': 'Chairman of the Board of Directors & CEO', 'yearBorn': 1979, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Hao-Yuan  Chuang C.F.A., F.R.M., M.B.A.', 'age': 39, 'title': 'CFO & Director', 'yearBorn': 1984, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nathan L. Mata Ph.D.', 'age': 57, 'title': 'Chief Scientific Officer', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}]
maxAge§86400
priceHint§2
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-0.73
exchange§NCM
quoteType§EQUITY
shortName§Belite Bio, Inc
longName§Belite Bio, Inc
firstTradeDateEpochUtc§1651239000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8f0c212f-6730-31e5-bde8-f751aab9807d
gmtOffSetMilliseconds§-18000000
targetHighPrice§60.0
targetLowPrice§45.0
targetMeanPrice§55.25
targetMedianPrice§58.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§4
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
